UNSPSC 51322803: Picafibrate

This classification denotes an anti-lipidemic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 12L83YI68T. European Medicines Agency schedules Picafibrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09806MIG. Picafibrate generally arises in the molecular formula C18H19CLN2O4. The term PICAFIBRATE is an International Non-Proprietary Name or INN. PICAFIBRATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule picafibrate under HS 29333999 and SITC 51574. As of Q4 2014, PICAFIBRATE remains the US FDA Preferred Term for this commodity. Picafibrate bears US NLM identifiers UMLS ID C0071029 and NCI Concept Code C72993. SMILES: Clc1ccc(OC(C)(C)C(=O)OCCNC(=O)c2cccnc2)cc1.

UNSPSC 51322803 Picafibrate is a Commodity code covering pharmaceutical ingredient procurement, though the recent state and local opportunities under this code reflect a broader portfolio of advanced life support medications, generic pharmaceuticals, and over-the-counter products being sourced by municipalities, state health agencies, and cooperative purchasing alliances. State and local governments buying under this code are acquiring emergency medical supplies for fire and rescue services, pharmacy benefit program fulfillment, and multi-state institutional distribution networks. The work includes sealed-bid procurement of specific medication line items with strict expiration and quality-assurance requirements, direct-to-manufacturer contracting exploration by state health agencies, and cooperative multi-vendor framework agreements requiring compliance with current Good Manufacturing Practices, Drug Supply Chain Security Act standards, and FDA requirements.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa Purchasing Department issued an IFB (Bid No. 26-P-00188) on April 24, 2026 for Advanced Life Support Medications to supply Tampa Fire Rescue with four medication line items including Labetalol, Epinephrine, Adenosine, and Diltiazem, with sealed bids due April 8, 2026 and an estimated contract value of $40,000.00 under a one-year term with optional renewals and a Small Local Business Enterprise sheltered-market designation offering a 5 percent bid discount. The Texas Health and Human Services Commission issued an RFI (HHS0017013) in early April 2026 to gather market intelligence on direct-to-manufacturer prescription programs and vendor capabilities for a planned Therapeutic Pharmacy Initiative, representing exploratory procurement without immediate award timelines or budget commitment. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued an RFP (S1070000015802) with a March 26, 2026 response deadline to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon, requiring wholesaler-certified vendors to supply products through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC with pricing evaluation weighted 75 percent on competitiveness and contract effectiveness July 1, 2026.